INBRAIN Neuroelectronics
Barcelona
About INBRAIN Neuroelectronics
INBRAIN Neuroelectronics is pioneering real time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $119.8M
- Funding stage: Early Stage Venture
- Last round: Grant (May 2025)
- Website: inbrain-neuroelectronics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical Device, Nanotechnology, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/inbrain-neuroelectronics-113727 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.